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TE TRAKIS-QUATERNARY AMMONIUM

receptors are located in the cell body and terminal areas of
these neurotransmitter systems. NIC facilitates neurotrans
mitter release from nerve terminals.

SALTS AND METHODS FOR MODULATING
NEURONAL NICOTINIC AC TEYLCHOLINE
RECEPTORS

The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of inter

CROSS-REFERENCE TO RELATED
APPLICATIONS

est in developing novel, subtype-selective agonists and/or
antagonists. Some of these agonists are currently being evalu
ated in clinical trials for cognitive enhancement and neuro

This application claims priority to US. Provisional Appli
cation Ser. No. 61/001,196 ?led Oct. 31, 2007, the entire
contents of Which are herein expressly incorporated herein by

protective effects, potentially bene?cial for disease states
such as schizophrenia, AlZheimer’s and Parkinson’s disease.

reference
SUMMARY OF INVENTION
FIELD OF THE INVENTION

In one embodiment, compounds corresponding to the fol
loWing structure are provided.

The invention relates to tetrakis-quaternary ammonium
salts and their use in modulating nicotinic acetylcholine

receptors.
BACKGROUND OF THE INVENTION

20

S(—)-Nicotine (NIC) activates presynaptic and postsynap
tic neuronal nicotinic receptors that evoke the release of neu

rotransmitters from presynaptic terminals and that modulate
the depolariZation state of the postsynaptic neuronal mem

25

brane, respectively. Thus, nicotine produces its effect by
binding to a family of ligand-gated ion channels, stimulated
by acetylcholine (ACh) or nicotine Which causes the ion
channel to open and cations to ?ux With a resulting rapid

(millisecond) depolarization of the target cell.

(CH2)m3

30

[3

Neuronal nicotinic receptors are composed of tWo types of
subunits, 0t and [3, and assemble as heteromeric receptors With
the general stoichiometry of 2a and 3[3 or as homomeric
receptors With 5a subunits. Nine subtypes of the ot subunit

(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are

(CHZM
35

found in the central nervous system. The mo st common nico

tinic receptor subtype in the brain is composed of tWo (X4 and

three [32 subunits, i.e., (X462. These subunits display different,
but overlapping, patterns of expression in the brain. Examples
of heteromeric receptor subtypes include (X462, (X362, (X3 [34,

40

(X662, (x40t5[32, (x60t5[32, (x40t6[32, (x4[32[34, (x3[32[34, and
others. The predominant homomeric subtype includes (x7, but
other combinations have also been proposed.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to
be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid
sequence at the subunit level and from the multiple combina
tions of assemblies of subunits into functional receptor pro
teins, Which affords a Wide diversity of pharmacological

Each X9 is independently an organic or inorganic anion.
Q is a phenyl group substituted at the 1-, 2-, 3- and 4-po
sitions, at the 1-, 2-, 3- and 5-positions, or at the 1-, 2-, 4- and

5-positions.
The values for m1, m2, m3 and m4 are each independently
0, 1, 2, 3, 4 or 5.
The values for n1, n2, n3 and n4 are each independently 1,

45

2, 3, 4 or 5.

L1, L2, L1 and L4 are each independently selected from
4CH2CH2i, cis iCH:CHi, trans iCH:CHi,
50

%ECi, iSiCHZi, %H2iSi, iSeiCHzi,
%H2iSei, iO%H2i, iCHziOi, iNHi

speci?city.

CHzi, iCH2iNHi, iN(loWer alkyl)-CH2i, 4CH2i

In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3H]NIC

N(loWer alkyl)-, iN:CHi, 4CH:Ni or iN:Ni.
Z1, Z2, Z3 and Z4 are each independently ?ve or six mem
bered rings as shoWn in formulas (HA) and (IIB), Wherein
each ring of Z1, Z2, Z3 and Z4 has one, tWo or three nitrogen

55

appears to label the same sites in the brain as [3H]ACh. It has

been estimated that over 90% of [3H]NIC binding in the brain
is due to association With the heteromeric receptor that is
composed of (X4 and [32 subunits. Also abundant in the central
nervous system are the homomeric receptors labeled by [3 H]

atoms.

60

methyllycaconitine (MLA), Which has high af?nity for the (X7
nicotinic receptor subtype. Nicotinic receptor subtypes can
be studied using functional assays, such as NIC-evoked neu

rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H]
norepinephrine (NE) release, [3H]serotonin (5-HT) release,
[3H]gamma-aminobutyric acid (GABA) release and [3 H]
glutamate release) from superfused rat brain slices. Nicotinic

65
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tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het
erocyclic, or substituted heterocyclic, and Where if Y2 com
prises alkenyl or alkynyl, the site of unsaturation is not

conjugated With the carbonyl group; 0Y3, Where Y3 is
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,

substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy

A1 is carbon or nitrogen, provided that WhenAl joins a ring

clic, or substituted heterocyclic, Where if Y3 comprises alk
enyl or alkynyl, the site of unsaturation is not conjugated With

atom With an unsaturated bond or is a nitrogen, R9 is absent,
and When A1 joins a ring atom With an unsaturated bond and
is a nitrogen, both R4 and R9 are absent.

the oxygen; NY4Y5 , Where Y4 and Y5 are each independently

selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy

A2 is carbon or nitrogen, provided that When A2 joins a ring
atom With an unsaturated bond or is a nitrogen, R10 is absent,
and When A2 joins a ring atom With an unsaturated bond and
is a nitrogen, both R5 and R10 are absent.

A3 is carbon or nitrogen, provided that When A3 joins a ring
atom With an unsaturated bond or is a nitrogen, R1 l is absent,

20

With the nitrogen; SY6, Where Y6 is selected from hydrogen,

A4 is carbon or nitrogen, provided that When A4 j oins a ring
atom With an unsaturated bond or is a nitrogen, R12 is absent,
and When A4 joins a ring atom With an unsaturated bond and
is a nitrogen, both R7 and R12 are absent.

25

A5 is carbon or nitrogen, provided that When A5 joins a ring
atom With an unsaturated bond or is a nitrogen, R13 is absent,
and When A5 joins a ring atom With an unsaturated bond and
is a nitrogen, both R8 and R13 are absent.

30

A6 is carbon or nitrogen, provided that When A6 joins a ring
atom With an unsaturated bond or is a nitrogen, R19 is absent,
and When A6 joins a ring atom With an unsaturated bond and
is a nitrogen, both R15 and R19 are absent.

A7 is carbon or nitrogen, provided that When A7 joins a ring

A8 is carbon or nitrogen, provided that When A8 joins a ring
40

In another embodiment, a composition is provided com
prising a pharmaceutically acceptable carrier and a com
pound as described above.
In another embodiment, a method is provided for selec

subject in need thereof.
In another embodiment, a method is provided for prevent
ing and/ or treating a central nervous system associated disor

der comprising administering a therapeutically effective
amount of a compound as described above to a mammalian
50

R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16,
R17, R18, R19, R20, R21, and R22, When present, are each
independently selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted

subject in need thereof.
In another embodiment, a method is provided for prevent
ing and/or treating substance use and/or abuse comprising
administering a therapeutically effective amount of a com

alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi
tuted arylalkynyl, heterocyclic, substituted heterocyclic,
halo, cyano, nitro, SOYl, SOZYI, SOZOYl or SO2NHY1,

55

where Y1 is selected from hydrogen, loWer alkyl, alkenyl,

60

pound as described above to a mammalian subject in need
thereof.

In another embodiment, a method is provided for prevent

ing and/ or treating gastrointestinal tract disorders comprising
administering a therapeutically effective amount of a com

alkynyl or aryl, and where Y1 is not hydrogen in SOYl and if
Y1 is alkenyl or alkynyl, the site of unsaturation is not conju
gated With a heteroatom; COY2, Where Y2 is selected from

hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi

heterocycle With one to three hetero atoms in the ring, or
substituted heterocycle With one to three hetero atoms in the
ring.

amount of a compound as described above to a mammalian
45

nium nitrogen is unsaturated, and R14 or R23 is a straight chain
or branched alkyl group of four carbons or feWer When all of
the bonds to the ammonium nitrogen are saturated.

substituted heterocyclic, and Where ifY6 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated With the
sulfur; or R4 and R5 together With A1 and A2, or R5 and R6
together With A2 and A3, or R15 and R1 6 together With A6 and
A7 or R1 6 and R1 7 together WithA7 andA8 independently form
a three to eight member cyclolkane, substituted cycloalkane,

tively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective

A9 is carbon or nitrogen, provided that When A9 joins a ring
atom With an unsaturated bond or is a nitrogen, R22 is absent,
and When A9 joins a ring atom With an unsaturated bond and
is a nitrogen, both R14 and R22 are absent.
R14 or R23 is absent When any of the bonds to the ammo

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or

cycloalkene, substituted cycloalkene, aryl, substituted aryl,
35

atom With an unsaturated bond or is a nitrogen, R20 is absent,
and When A7 joins a ring atom With an unsaturated bond and
is a nitrogen, both R16 and R20 are absent.
atom With an unsaturated bond or is a nitrogen, R21 is absent,
and When A8 joins a ring atom With an unsaturated bond and
is a nitrogen, both R17 and R21 are absent.

clic, or substituted heterocyclic, Where ifY4 orY5 comprises
alkenyl or alkynyl, the site of unsaturation is not conjugated

and When A3 joins a ring atom With an unsaturated bond and
is a nitrogen, both R6 and R11 are absent.

pound as described above to a mammalian subject in need
thereof.

Other methods, features and advantages of the present
invention Will be or become apparent to one With skill in the

65

art upon examination of the folloWing detailed descriptions. It
is intended that all such additional methods, features and
advantages be included Within this description, be Within the
scope of the present invention, andbe protected by the accom

panying claims.
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BRIEF DESCRIPTION OF THE DRAWINGS

cycloalkyl” refers to cycloalkyl moieties further bearing one
or more substituents as set forth above.

The term “alkenyl” refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon double
bond and having 2 to 19 carbon atoms, and “substituted
alkenyl” refers to alkenyl groups further bearing one or more

FIG. 1 shows the concentration dependent inhibition by

compounds ZZ-208G (FIG. 1A) and ZZ-280F (FIG. 1B) on
the effect of nicotine to evoke [3H]dopamine release.

substituents as set forth above.

DETAILED DESCRIPTION OF INVENTION

The term “alkynyl” refers to straight or branched chain

hydrocarbyl moieties having at least one carbon-carbon triple
bond and having 2 to 19 carbon atoms, and “substituted
alkynyl” refers to alkynyl moieties further bearing one or

Before the present compositions and methods are
described, it is to be understood that the invention is not

limited to the particular methodologies, protocols, assays,

more substituents as set forth above.

and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to

The term “aryl” refers to aromatic groups having 6 to 24
carbon atoms, and “substituted aryl” refers to aryl groups

describe particular embodiments of the present invention, and

further bearing one or more substituents as set forth above.

is in no Way intended to limit the scope of the present inven
tion as set forth in the appended claims.
It must be noted that as used herein and in the appended

The term “alkylaryl” refers to alkyl-substituted aryl
groups, and “substituted alkylaryl” refers to alkylaryl groups

claims, the singular forms “a,” “an,” and “the” include plural

The term “arylalkyl” refers to aryl-substituted alkyl
groups, and “substituted arylalkyl” refers to arylalkyl groups

references unless the context clearly dictates otherWise.
Unless de?ned otherWise, all technical and scienti?c terms
used herein have the same meanings as commonly under
stood by one of ordinary skill in the art to Which this invention
belongs. All publications cited herein are incorporated herein

further bearing one or more substituents as set forth above.

20

The term “arylalkenyl” refers to aryl-substituted alkenyl
groups, and “substituted arylalkenyl” refers to arylalkenyl
groups further bearing one or more substituents as set forth

above.

by reference in their entirety for the purpose of describing and

disclosing the methodologies, reagents, and tools reported in

25

the publications that might be used in connection With the

above.
The term “heterocyclic” refers to cyclic moieties contain

that the invention is not entitled to antedate such disclosure by
30

endogenous acetylcholine receptor having binding sites for

The term “acyl” refers to alkyl-carbonyl groups, and “sub
stituted acyl” refers to acyl groups further bearing one or

acetylcholine receptor.”

35 more substituents as set forth above.

The term “halogen” refers to ?uoride, chloride, bromide or
iodide groups.
It is understood that in all substituted groups de?ned above,

ous subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or hetero
meric complex, or multiple homomeric or heteromeric com

plexes.

40

The term “agonist” refers to a substance Which interacts
With a receptor and increases or prolongs a physiological

response of that receptor.
The terms “disorder,” “disease,” and “condition” are used
inclusively and refer to any status deviating from normal.

polymers arrived at by de?ning sub stituents With further sub
stituents to themselves (e. g. substituted aryl having a substi
tuted aryl group as a substituent Which is itself substituted
With a substituted aryl group, etc.) are not intended for inclu
sion herein. In such cases, the maximum number of such
substituents is three. That is to say that each of the above

response (i.e. activates the receptor).
The term “partial agonist” refers to a substance Which
interacts With and activates a receptor to a lesser degree than
an agonist.
The term “antagonist” refers to a substance Which interacts
With and decreases the extent or duration of a physiological

ing one or more heteroatoms as part of the ring structure and

having 3 to 24 carbon atoms, and “substituted heterocyclic”
refers to heterocyclic moieties further bearing one or more
substituents as set forth above.

acetylcholine Which also bind to nicotine. The term “nicotinic
acetylcholine receptor” includes the term “neuronal nicotinic

The terms “subtype of nicotinic acetylcholine receptor,”
and “nicotinic acetylcholine receptor subtype” refer to vari

The term “arylalkynyl” refers to aryl-substituted alkynyl
groups, and “substituted arylalkynyl” refers to arylalkynyl
groups further bearing one or more substituents as set forth

invention. Nothing herein is to be construed as an admission

virtue of prior invention.
The term “nicotinic acetylcholine receptor” refers to the

further bearing one or more substituents as set forth above.

45

de?nitions is constrained by a limitation that, for example,
substituted aryl groups are limited to -substituted aryl-(sub

stituted aryl)-sub stituted aryl.
Compounds of the present invention are tetrakis-quater
nary ammonium salts corresponding to Formula (I):
50

The term “central nervous system associated disorders”

includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,
such as disorders associated With the alteration of normal
neurotransmitter release in the brain.
The term “loWer alkyl” refers to straight or branched chain
alkyl radicals having in the range of l to 4 carbon atoms.
The term “alkyl” refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and “substituted alkyl”

55

60

refers to alkyl radicals further bearing one or more substitu

ents including, but not limited to, hydroxy, alkoxy (of a loWer

alkyl group), mercapto (of a loWer alkyl group), aryl, hetero
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car
boxyl, carbamate, sulfonyl, and sulfonamide.

65

The term “cycloalkyl” refers to cyclic ring-containing moi
eties containing 3 to 8 carbon atoms, and “substituted

Each X9 is independently an organic or inorganic anion.
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Q is a phenyl group substituted at the 1-, 2-, 3- and 4-po
sitions, at the 1-, 2-, 3- and 5-positions, or at the 1-, 2-, 4- and

and When A8 joins a ring atom With an unsaturated bond and
is a nitrogen, both R17 and R21 are absent.

5-positions.

A9 is carbon or nitrogen, provided that WhenA9 joins a ring

The values for m1, m2, m3 and m4 are each independently
0, 1, 2, 3, 4 or 5.
The values for n1, n2, n3 and n4 are each independently 1,
2, 3, 4 or 5.

atom With an unsaturated bond or is a nitrogen, R22 is absent,
and When A9 joins a ring atom With an unsaturated bond and
is a nitrogen, both R14 and R22 are absent.
R14 or R23 is absent When any of the bonds to the ammo

L1, L2, L3 and L4 are each independently selected from
iCH2CH2i, cis 4CH:CHi, trans 4CH:CHi,

nium nitrogen is unsaturated, and R14 or R23 is a straight chain
or branched alkyl group of four carbons or feWer When all of
the bonds to the ammonium nitrogen are saturated.

*CECi, iS%H2i, %H2iSi, iSeiCH2i,
iCHZiSei, iO%H2i, iCHziOi, iNHi
CHzi, iCHZiNHi, iN(loWer alkyl)-CH2i, 4CH2i

R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16’

N(loWer alkyl)-, iN:CHi, 4CH:Ni or iN:Ni.
Z1, Z2, Z3 and Z4 are each independently ?ve or six mem
bered rings as shown in formulas (11A) and (11B), Wherein
each ring of Z1, Z2, Z3 and Z4 has one, tWo or three nitrogen
atoms.
20

(HA)

R17, R18, R19, R20, R21, and R22, When present, are each
independently selected from hydrogen, alkyl, substituted
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi
tuted arylalkynyl, heterocyclic, substituted heterocyclic,
halo, cyano, nitro, SOYl, SOZYI, SOZOYl or SO2NHY1,
where Y1 is selected from hydrogen, loWer alkyl, alkenyl,
alkynyl or aryl, and WhereYl is not hydrogen in SOYl and if
Y1 is alkenyl or alkynyl, the site of unsaturation is not conju
gated With a heteroatom; COY2, Where Y2 is selected from

25

hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het

30

erocyclic, or substituted heterocyclic, and Where if Y2 com
prises alkenyl or alkynyl, the site of unsaturation is not

(HE)

A1 is carbon or nitrogen, provided that WhenAl joins a ring

conjugated With the carbonyl group; 0Y3, Where Y3 is
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,

atom With an unsaturated bond or is a nitrogen, R9 is absent,
and When A1 joins a ring atom With an unsaturated bond and
is a nitrogen, both R4 and R9 are absent.

clic, or substituted heterocyclic, Where if Y3 comprises alk
enyl or alkynyl, the site of unsaturation is not conjugated With

35

acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy
40

the oxygen; NY4Y5 , Where Y4 and Y5 are each independently

A2 is carbon or nitrogen, provided that When A2 joins a ring
atom With an unsaturated bond or is a nitrogen, R10 is absent,
and When A2 joins a ring atom With an unsaturated bond and
is a nitrogen, both R5 and R10 are absent.

A3 is carbon or nitrogen, provided that When A3 joins a ring

45

atom With an unsaturated bond or is a nitrogen, R1 1 is absent,

and When A3 joins a ring atom With an unsaturated bond and
is a nitrogen, both R6 and R11 are absent.

A4 is carbon or nitrogen, provided that When A4 j oins a ring

clic, or substituted heterocyclic, Where ifY4 orY5 comprises
alkenyl or alkynyl, the site of unsaturation is not conjugated
50

With the nitrogen; SY6, Where Y6 is selected from hydrogen,

55

alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or

atom With an unsaturated bond or is a nitrogen, R12 is absent,
and When A4 joins a ring atom With an unsaturated bond and
is a nitrogen, both R7 and R12 are absent.

A5 is carbon or nitrogen, provided that When A5 joins a ring
atom With an unsaturated bond or is a nitrogen, R13 is absent,
and When A5 joins a ring atom With an unsaturated bond and
is a nitrogen, both R5 and R13 are absent.

selected from hydrogen, alkyl, substituted alkyl, cycloalkyl,
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl,
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy

substituted heterocyclic, and Where ifY6 comprises alkenyl or
alkynyl, the site of unsaturation is not conjugated With the
sulfur; or R4 and R5 together With A1 and A2, or R5 and R6
together With A2 and A3, or R15 and R1 6 together With A6 and

A6 is carbon or nitrogen, provided that When A6 joins a ring
atom With an unsaturated bond or is a nitrogen, R19 is absent,
and When A6 joins a ring atom With an unsaturated bond and
is a nitrogen, both R15 and R19 are absent.

A7, or R16 and R17 together With A7 and A8 independently

A7 is carbon or nitrogen, provided that When A7 joins a ring

kane, cycloalkene, substituted cycloalkene, aryl, substituted

atom With an unsaturated bond or is a nitrogen, R20 is absent,
and When A7 joins a ring atom With an unsaturated bond and
is a nitrogen, both R16 and R20 are absent.

aryl, heterocycle With one to three hetero atoms in the ring, or
substituted heterocycle With one to three hetero atoms in the
ring.

form a three to eight member cyclolkane, substituted cycloal

65

A8 is carbon or nitrogen, provided that When A8 joins a ring

For example, Z1, Z2, Z1 and Z4 include pyrrole, pyrrolidine,

atom With an unsaturated bond or is a nitrogen, R21 is absent,

pyraZole, imidaZole, 1,2,3-triaZole, 1,2,4-triaZole, pyridine,

US 8,629,163 B2
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piperidine, quinoline, tetrahydroquinoline, isoquinoline, tet
rahydroisoquinoline, pyraZine, piperaZine, pyridaZine, and

incorporated by reference. The above salt forms may be in

triaZine.

Vents.

As another example, R4, R5, R6, R7, R8, R9, R10, R11, R12,
R13, R15,R16,Rl7R18, R19, R2O,R21, and R22, include hydro
gen, methyl, ethyl, propyl, butyl, tri?uoromethyl, hydroxym
ethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, phenyl,
benZyl, pyrrolidine, N-alkyl pyrrolidine (for example Where

In a compound of Formula (I), preferably the phenyl ring of
Q is substituted at the l-, 2-, 4- and 5-positions.

some cases hydrates or solvates With alcohols and other sol

In a compound of Formula (I), preferably A1, A2, A3, A4,
and A5 are carbon.

the alkyl chain is methyl, ethyl or propyl), unsaturated pyr

In a compound of Formula (I), preferably Z1, Z2, Z3 and Z4
are substituted, six-membered, aromatic rings. More prefer

rolidine, unsaturated N-alkyl pyrrolidine (for example Where

ably, Z1, Z2, Z3 and Z4 are substituted pyridinium rings.

the alkyl chain is methyl, ethyl or propyl), aZiridine, N-methyl
aZiridine, aZetidine, N-methyl aZetidine, unsaturated aZeti

In a compound of Formula (I), preferably R4 is hydrogen.
In a compound of Formula (I), preferably R5 is hydrogen,

dine, unsaturated N-methyl aZetidine, piperidine, N-methyl
piperidine, unsaturated piperidine, unsaturated N-methyl

nyl, or forms a six-membered ring With A2, A3 and R6. More

piperidine, aZepane, N-methyl aZepane, unsaturated aZepane,
unsaturated N-methyl aZepane, aZocane, N-methyl aZocane,
unsaturated aZocane, unsaturated N-methyl aZocane, l-aZa

benZyl, l-methyl-2-pyrrolidinyl, forms a phenyl group With
A2, A3 and R6, or forms a cyclohexyl group With A2, A3 and

bicyclo[3.2.l]octane, l-aZa-bicyclo[2.2.l]heptane, 8-me

R6.

thyl-8-aZa-bicyclo[3.2.l]octane,

alkyl, hydroxyalkyl, phenyl, benZyl, l-methyl-2-pyrrolidi
preferably, R5 is hydrogen, methyl, hydroxypropyl, phenyl,

l-aZa-tricyclo[3.3.l.l3’7]

decane, methyl cycloalkyl, methyl substituted cycloalkyl,

In a compound of Formula (I), preferably R6 is hydrogen,
20

alkyl, forms a phenyl group With A2, A3 and R5, or forms a

methylpyrrolidine, methyl N-alkyl pyrrolidine (for example

cyclohexyl group With A2, A3 and R5. More preferably, R6 is

Where the alkyl chain is methyl, ethyl or propyl), methyl

hydrogen, methyl, forms a phenyl group With A2, A3 and R5 ,

unsaturated pyrrolidine, methyl unsaturated N-alkyl pyrroli

or forms a cyclohexyl group With A2, A3 and R5 .

dine (for example Where the alkyl chain is methyl, ethyl or

In a compound of Formula (I), preferably R7 is hydrogen or

propyl), methyl aZiridine, methyl N-methyl aZiridine, methyl
aZetidine, methyl N-methyl aZetidine, methyl unsaturated
aZetidine, methyl unsaturated N-methyl aZetidine, methyl
piperidine, methyl N-methyl piperidine, methyl unsaturated
piperidine, methyl unsaturated N-methyl piperidine, methyl

25

aZepane, methyl N-methyl aZepane, methyl unsaturated

30

m4:0.

In a compound of Formula (I), preferably n1, n2, n3 and

are %H2%H2i or iCECi.

In a compound of Formula (I), preferably X9 is a halogen.

More preferably, X9) is bromide.
35

[3.3.l.l3’7]decane.
As a further example, When R4 and R5 together WithAl and
A2, or R5 and R6 together With A2 and A3, or R15 and R16
together With A6 and A7, or R16 and R17 together With A7 and
A8 independently form a three to eight-membered ring, that

40

R5 is hydrogen, methyl, hydroxypropyl, phenyl, benZyl,

45

l-methyl-2-pyrrolidinyl, forms a phenyl group With A2, A3
and R6, or forms a cyclohexyl group With A2, A3 and R6;
Wherein R6 is hydrogen, methyl, forms a phenyl group With
A2, A3 and R5, or forms a cyclohexyl group With A2, A3 and
R5; and Wherein X9 is Br.
In another embodiment, the compound of Formula (I) is
de?ned Wherein the phenyl ring of Q is l,2,4,5-substituted;
Wherein ml, m2, m3 and m4:0; Wherein n1, n2, n3 and n4:3;
Wherein L is iCHZCHZi; wherein Z1, Z2, Z3 and Z4 are

(for example nitrogen, oxygen or sulfur) in the ring, and
further may be substituted With one or more substituents. For

thiophene, benZo[c]thiophene, indole, indolenine, isoindole,
cyclopental[b]pyridine, pyrano[3,4-b]pynrole, indaZole,
indoxaZine, benZoxaZole, anthranil naphthalene, tetralin,
decalin, chromene, coumarin, chroman-4-one, isocoumarin,
isochromen-3-one, quinoline, isoquinoline, 5,6,7,8-tetrahy
dro-isoquinoline, cinnoline, quinaZoline, naphthyrdine,
pyrido[3,4-b]-pyridine, pyridol[3,2-b]pyridine, pyrido[4,3,
b]-pyridine, benZoxaZine, anthracene, phenanthrene, phe
nalene, ?uorene, caraZole, xanthene, acnidine, octahydro-[l]
pyridine, l-methyloctahydro-[l]pyridine, octahydroindole,
l-methyloctahydro-indole, octahydro-cyclopenta[b]pyrrole,
l-methyloctahydro-cyclopenta[b]pyrrole, decahydroquino

50

2-pyrrolidinyl, forms a phenyl group With A2, A3 and R6, or
forms a cyclohexyl group With A2, A3 and R6; Wherein R6 is
hydrogen, methyl, forms a phenyl group With A2, A3 and R5,
55

60

ceutically acceptable salts listed in the Journal of Pharmaceu
tical Sciences Volume 66, page 2, 1977, Which are hereby

or forms a cyclohexyl group With A2, A3 and R5 ; and Wherein
X9 is Br.
In another embodiment, the compound of Formula (I) is

de?ned Wherein the phenyl ring of Q is l,2,4,5-substituted;
Wherein ml, m2, m3 and m4:0; Wherein n1, n2, n3 and n4:3;
Wherein L is 4CECi; wherein Z1, Z2, Z3 and Z4 are pyri
dinium rings; Wherein R4 is hydrogen; Wherein R5 is hydro

gen, methyl, hydroxypropyl, phenyl, benZyl, l-methyl-2-pyr
rolidinyl, forms a phenyl group With A2, A3 and R6, or forms

ate, tartrate, oxalate, succinate, or similar pharmaceutically

acceptable organic acid addition salts, including the pharma

pyridinium rings; Wherein R4 is hydrogen; Wherein R5 is

hydrogen, methyl, hydroxypropyl, phenyl, benZyl, l-methyl

line, and l-methyldecahydroquinoline.
X9, for example, includes F‘, Cl‘, Br‘, I‘, N02‘, H804‘,

S04“, HPO4_, PO42“, methanesulfonate, tri?uoromethane
sulfate, p-toluenesulfonate, benZenesulfonate, salicylate,
proprionate, ascorbate, aspartate, fumarate, galactarate,
maleate, citrate, glutamate, glycolate, lactate, malate, male

In one embodiment, the compound of Formula (I) is

de?ned Wherein the phenyl ring of Q is l,2,4,5-substituted;
Wherein ml, m2, m3 and m4:0; Wherein n1, n2, n3 and n4:3;
Wherein L is 4CH2CH2i or iCECi; wherein Z1, Z2, Z3
and Z4 are pyridinium rings; Wherein R4 is hydrogen; Wherein

ring may be a heterocycle containing up to three hetero atoms

example, possible rings include benZene, pyridine, pyran,
indene, isoindene, benZofuran, isobenZofuran, benZo [b]

n4:3.

In a compound of Formula (I), preferably L1, L2, L3 and L4

aZepane, methyl unsaturated N-methyl aZepane, methyl aZo
cane, methyl N-methyl aZocane, methyl unsaturated aZocane,

methyl unsaturated N-methyl aZocane, methyl-l -aZa-bicyclo
[3.2.1]octane, methyl-l-aZa-bicyclo[2.2.l]heptane, 8-me
thyl-8-aZa-bicyclo[3.2.l]octane, and methyl-l-aZa-tricyclo

alkyl. More preferably, R7 is hydrogen or methyl.
In a compound of Formula (I), preferably R8 is hydrogen.
In a compound of Formula (I), preferably ml, m2, m3 and

65

a cyclohexyl group With A2, A3 and R6; Wherein R6 is hydro
gen, methyl, forms a phenyl group With A2, A3 and R5, or
forms a cyclohexyl group With A2, A3 and R5; and Wherein
X9 is Br.
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Exemplary compounds of the present invention include:

In one embodiment, the present invention relates to a

5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl
(3-methylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl
(4-methylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl
(3,4-dimethylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl
(3,5-dimethylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl
nicotinium) tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis[4-pentyn-1-yl
(5,6,7,8-tetrahydroisoquinolinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl
(3-phenyl-pyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis(4-pentyn-1-yl
isoquinolinolinium)tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[4-pentyn-1-yl
(3-benZyl-pyridinium)]tetrabromide;

method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mam
malian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the

5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis {4-pentyn-1
yl- [3 -(3 -hydroxypropyl)-pyridinium] }tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3
methylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(4
methylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3,4
dimethylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3,5
dimethylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl
(nicotinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3
(3-hydroxypropanyl)pyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(iso
quinolinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3
benZylpyridinium)]tetrabromide;
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(3

compound of Formula (I) may selectively bind to one or more

subtypes of nicotinic acetylcholine receptor. The compound
of Formula (I) may act as an agonist or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a
neurotransmitter from a central nervous system tissue. The

neurotransmitter affected may include dopamine, norepi

nephrine, serotonin, gamma-aminobutyric acid, or glutamate.
Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
20

dopamine, norepinephrine, serotonin, gamma-aminobutyric
25

acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby
increasing or decreasing the likelihood of ?ring an action
potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

cholinergic response.
30

In another embodiment, the present invention is directed to
a method for preventing and/or treating a central nervous

system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
35

compound of Formula (I) may selectively bind to one or more

subtypes of nicotinic acetylcholine receptor. The compound
of Formula (I) may act as an agonist or partial agonist of
nicotinic acetylcholine receptor function. Hence the com
pound of Formula (I) may increase or prolong the release of a

phenylpyridinium)]tetrabromide; and

5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis[pentanyl-(5,6,
7,8-tetrahydroisoquinolinium)]tetrabromide.

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

40

neurotransmitter from a central nervous system tissue. The

neurotransmitter affected may include dopamine, norepi

The compounds of the present invention may contain one

nephrine, serotonin, gamma-aminobutyric acid, or glutamate.

or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as Well as racemic

Alternatively, the compound of Formula (I) may act as an

mixtures. The compounds can be separated into substantially

antagonist of nicotinic acetylcholine receptor function.
45

Hence the compound of Formula (I) may decrease the extent

optically pure compounds. The compounds of the present

or duration of the release of a neurotransmitter from a central

invention can be prepared by any applicable method knoWn
by those of skill in the art, including synthesis from corre
sponding free bases by reaction With an appropriate alkyl

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

bromide.
The compounds of the invention are nicotinic acetylcho

50

line receptor agents. Thus, they may augment or inhibit [3 H]
nicotine binding, [3H]MLA binding, evoke or inhibit neu

increasing or decreasing the likelihood of ?ring an action

rotransmitter release, and/or evoke or inhibit the ?ux of ions

through the nicotinic receptor. Moreover, the compounds of

dopamine, norepinephrine, serotonin, gamma-aminobutyric
acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

the invention may act either at presynaptic sites or postsyn

potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

aptic sites, for example, at a postsynaptic acetylcholine recep

cholinergic response.

tor containing an (X7 subunit. When acting at a postsynaptic
site, neurotransmitter release per se is not altered. Rather, the

according to the method of the present invention include

compounds of the invention may act by interacting With a

55

Central nervous system disorders Which may be treated
60

AlZheimer’s disease, dementia, cognitive dysfunctions (in

postsynaptic acetylcholine receptor to change the membrane
potential of the cell, thereby increasing or decreasing the

cluding disorders of attention, focus and concentration),
attention de?cit disorders, affective disorders, extrapyrami

likelihood of ?ring an action potential. Alternatively, interac

dal motor function disorders, Parkinson’s disease, progres

more second messenger systems Within the cell so as to

sive supramolecular palsy, Huntington’s disease, Gilles de la
Tourette syndrome, tardive dyskinesia, neuroendocrine dis
orders, dysregulation of food intake, disorders of nociception,

decrease or increase the nicotinic cholinergic response.

pain, including nociceptive pain and neuropathic pain, mood

tion of a compound of the invention With a postsynaptic
acetylcholine receptor may result in the alteration of one or

65
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and emotional disorders, depression, panic anxiety, psycho

an action potential, or to alter one or more second messenger

sis, schizophrenia, or epilepsy.

systems Within the cell so as to decrease or increase the

nicotinic cholinergic response.
Gastrointestinal disorders Which may be treated according

In yet another embodiment, the present invention is
directed to a method for preventing and/ or treating sub stance
use and/or abuse comprising administering to a mammalian
subject in need thereof a therapeutically effective amount of a

to the method of the present invention include irritable boWel

syndrome, colitis, diarrhea, constipation, gastric acid secre

compound of Formula (I). In such a method, the compound of

tion or ulcers.

The compounds of the present invention can be delivered

Formula (I) may selectively bind to one or more subtypes of

directly or in pharmaceutical compositions along With suit

nicotinic acetylcholine receptors. The compound of Formula
(I) may act as an agonist or partial agonist of nicotinic ace

able carriers or excipients, as is Well knoWn in the art. For

tylcholine receptor function. Hence the compound of For

example, a pharmaceutical composition of the invention may

mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue. The

include a conventional additive, such as a stabiliZer, buffer,

salt, preservative, ?ller, ?avor enhancer and the like, as knoWn
to those skilled in the art. Exemplary buffers include phos

neurotransmitter affected may include dopamine, norepi

nephrine, serotonin, gamma-aminobutyric acid, or glutamate.

phates, carbonates, citrates and the like. Exemplary preserva
tives include EDTA, EGTA, BHA, BHT and the like.

Alternatively, the compound of Formula (I) may act as an

antagonist of nicotinic acetylcholine receptor function.

An effective amount of such agents can readily be deter
mined by routine experimentation, as can the most effective
and convenient route of administration and the most appro

Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central

nervous system tissue. In this regard, the compound of For
mula (I) may act by decreasing stimulant-evoked neurotrans
mitter release. The neurotransmitter affected may include

20

priate formulation. Various formulations and drug delivery
systems are available in the art. See, e.g., Gennaro, A. R., ed.

(1995) Remington’s Pharmaceutical Sciences.

dopamine, norepinephrine, serotonin, gamma-aminobutyric

Suitable routes of administration may, for example,

acid, or glutamate. Alternatively, the compound of Formula
(I) may act by interacting With a postsynaptic acetylcholine
receptor to change the membrane potential of the cell thereby

include oral, rectal, transmucosal, nasal, or intestinal admin
25

istration and parenteral delivery, including intramuscular,
subcutaneous, intramedullary injections, as Well as intrathe

increasing or decreasing the likelihood of ?ring an action

cal, direct intraventricular, intravenous, intraperitoneal, intra

potential, or to alter one or more second messenger systems
Within the cell so as to decrease or increase the nicotinic

nasal, or intraocular injections. In addition, the agent or com
position thereof may be administered sublingually or via a
spray, including a sublingual tablet or a sublingual spray. The
agent or composition thereof may be administered in a local
rather than a systemic manner. For example, a suitable agent
can be delivered via injection or in a targeted drug delivery

cholinergic response.

30

The conditions of substance use and/or abuse treated

according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),

nicotine intoxication, amphetamine abuse, methamphet
amine abuse, MDMA (methylenedioxymethamphetamine)
abuse, methylphenidate abuse, cocaine abuse, or alcohol

system, such as a depot or sustained release formulation.
35

the art, such as by conventional mixing, dissolving, granulat

abuse.
In another embodiment, the present invention is directed to

a method for preventing and/or treating gastrointestinal tract
disorders comprising administering to a mammalian subject

ing, dragee-making, levigating, emulsifying, encapsulating,
entrapping, or lyophiliZing processes. As noted above, the
40

pound of Formula (I). In such a method, the compound of
Formula (I) may selectively bind to one or more subtypes of

nicotinic acetylcholine receptor. The compound of Formula
45

tylcholine receptor function. Hence the compound of For
mula (I) may increase or prolong the release of a neurotrans
mitter from a central nervous system tissue, or may increase
or prolong the release of a neurotransmitter from a peripheral
nervous system tissue, or may act directly on a gastrointesti
nal tract tissue. The neurotransmitter affected may include

compositions of the present invention can include one or

more physiologically acceptable carriers such as excipients
and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of admin

in need thereof a therapeutically effective amount of a com

(I) may act as an agonist or partial agonist of nicotinic ace

The pharmaceutical compositions of the present invention
may be manufactured by any of the methods Well-knoWn in

50

dopamine, norepinephrine, serotonin, gamma-aminobutyric

istration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in physi
ologically compatible buffers such as Hanks’ solution, Ring
er’ s solution, or physiological saline buffer. For transmucosal
or nasal administration, penetrants appropriate to the barrier
to be permeated are used in the formulation. Such penetrants
are generally knoWn in the art. In a preferred embodiment of

the present invention, the present compounds are prepared in

acid, or glutamate. Alternatively, the compound of Formula

a formulation intended for oral administration. For oral

(I) may act as an antagonist of nicotinic acetylcholine recep
tor function. Hence the compound of Formula (I) may

administration, the compounds can be formulated readily by
combining the active compounds With pharmaceutically

55

acceptable carriers Well knoWn in the art. Such carriers enable
the compounds of the invention to be formulated as tablets,

decrease the extent or duration of the release of a neurotrans
mitter from a central nervous system tissue, or may decrease
the extent or duration of the release of a neurotransmitter from
a peripheral nervous system tissue, or may act directly on a

gastrointestinal tract tissue. In this regard, the compound of
Formula (I) may act by decreasing stimulant-evoked neu

pills, dragees, capsules, liquids, gels, syrups, slurries, suspen
60

suppositories or retention enemas, e.g., containing conven
tional suppository bases such as cocoa butter or other glyc
erides.
Pharmaceutical preparations for oral use can be obtained as

rotransmitter release. The neurotransmitter affected may

include dopamine, norepinephrine, serotonin, gamma-ami
nobutyric acid, or glutamate. Alternatively, the compound of
Formula (I) may act by interacting With a postsynaptic ace

tylcholine receptor to change the membrane potential of the
cell thereby increasing or decreasing the likelihood of ?ring

sions and the like, for oral ingestion by a subject. The com
pounds may also be formulated in rectal compositions such as

65

solid excipients, optionally grinding a resulting mixture, and
processing the mixture of granules, after adding suitable aux
iliaries, if desired, to obtain tablets or dragee cores. Suitable
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excipients are, in particular, ?llers such as sugars, including
lactose, sucrose, mannitol, or sorbitol; cellulose preparations
such as, for example, maize starch, Wheat starch, rice starch,

tain substances that increase the viscosity of the suspension,

potato starch, gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcel
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin

ers or agents that increase the solubility of the compounds to

such as sodium carboxymethyl cellulose, sorbitol, or dextran.

Optionally, the suspension may also contain suitable stabiliz

alloW for the preparation of highly concentrated solutions.
Alternatively, the active ingredient may be in poWder form for

tegrating agents may be added, such as cross-linkedpolyvinyl

constitution With a suitable vehicle, e.g., sterile pyrogen-free

pyrrolidone, agar, or alginic acid or a salt thereof such as

Water, before use.

sodium alginate. Also, Wetting agents such as sodium dodecyl

As mentioned above, the compositions of the present

sulfate may be included.
Dragee cores are provided With suitable coatings. For this
purpose, concentrated sugar solutions may be used, Which

invention may also be formulated as a depot preparation.

Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscu
larly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated With suitable poly

may optionally contain gum arabic, talc, polyvinyl pyrroli
done, carbopol gel, polyethylene glycol, and/or titanium
dioxide, lacquer solutions, and suitable organic solvents or

meric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.

solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identi?cation or to characterize
different combinations of active compound doses.

Pharmaceutical preparations for oral administration
include push-?t capsules made of gelatin, as Well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-?t capsules can contain the
active ingredients in admixture With ?ller such as lactose,

Suitable carriers for the hydrophobic molecules of the
invention are Well knoWn in the art and include co-solvent
20

surfactant, a Water-miscible organic polymer, and an aqueous
phase. The co-solvent system may be the VPD co-solvent
system. VPD is a solution of 3% W/v benzyl alcohol, 8% W/v

binders such as starches, and/or lubricants such as talc or

magnesium stearate and, optionally, stabilizers. In soft cap
sules, the active compounds may be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraf?n, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages

25

suitable for such administration.
In one embodiment, the compounds of the present inven
tion can be administered transdermally, such as through a skin
patch, or topically. In one aspect, the transdermal or topical
formulations of the present invention can additionally com
prise one or multiple penetration enhancers or other effectors,
including agents that enhance migration of the delivered com
pound. Transderrnal or topical administration could be pre

30

ferred, for example, in situations in Which location speci?c
delivery is desired. Methods of transdermal delivery include
microneedle transdermal delivery.
For administration by inhalation, the compounds for use
according to the present invention are conveniently delivered

solvent system is effective in dissolving hydrophobic com

pounds and produces loW toxicity upon systemic administra

vent components may be varied. For example, other loW
toxicity nonpolar surfactants may be used instead of
35

Alternatively, other delivery systems for hydrophobic mol
40

above in the context of gene-delivery systems. Certain
organic solvents such as dimethylsulfoxide also may be
45

employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sus
tained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustained

50

release materials are established and available to those of skill

These typically contain a poWder mix of the compound and a

in the art. Sustained-release capsules may, depending on their
chemical nature, release the compounds for a feW Weeks up to
over 100 days. Depending on the chemical nature and the

suitable poWder base such as lactose or starch.

Compositions formulated for parenteral administration by
injection, e. g., by bolus injection or continuous infusion can
55

ment, a therapeutically effective dose can be estimated ini

tially using a variety of techniques Well knoWn in the art. For
60

include aqueous solutions or other compositions in Water
soluble form.

Suspensions of the active compounds may also be prepared

as appropriate oily injection suspensions. Suitable lipophilic
solvents or vehicles include fatty oils such as sesame oil and

biological stability of the therapeutic reagent, additional
strategies for stabilization may be employed.
For any composition used in the present methods of treat

multi-dose containers, With an added preservative. The com
positions may take such forms as suspensions, solutions, or
emulsions in oily or aqueous vehicles, and may contain for

synthetic fatty acid esters, such as ethyl oleate or triglycer
ides, or liposomes. Aqueous injection suspensions may con

ecules may be employed. Liposomes and emulsions are Well
knoWn examples of delivery vehicles or carriers for hydro

phobic drugs. Liposomal delivery systems are discussed

metered amount. Capsules and cartridges of, for example,

mulatory agents such as suspending, stabilizing and/or dis
persing agents. Formulations for parenteral administration

polysorbate 80, the fraction size of polyethylene glycol may
be varied, other biocompatible polymers may replace poly
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars
or polysaccharides may substitute for dextrose.

rotetra?uoroethane, carbon dioxide, or any other suitable gas.
In the case of a pressurized aerosol, the appropriate dosage
unit may be determined by providing a valve to deliver a

be presented in unit dosage form, e.g., in ampoules or in

tion. Naturally, the proportions of a co-solvent system may be

varied considerably Without destroying its solubility and tox
icity characteristics. Furthermore, the identity of the co-sol

packs or a nebulizer, With the use of a suitable propellant, e.g.,

gelatin, for use in an inhaler or insuf?ator may be formulated.

of the nonpolar surfactant polysorbate 80, and 65% W/v poly
ethylene glycol 300, made up to volume in absolute ethanol.
The VPD co-solvent system (VPDzSW) consists of VPD
diluted 1:1 With a 5% dextrose in Water solution. This co

in the form of an aerosol spray presentation from pressurized

dichlorodi?uoromethane, trichloro?uoromethane, dichlo

systems comprising, for example, benzyl alcohol, a nonpolar

65

example, in a cell culture assay, a dose can be formulated in
animal models to achieve a circulating concentration range

that includes the IC5O as determined in cell culture. Dosage
ranges appropriate for human subjects can be determined, for
example, using data obtained from cell culture assays and
other animal studies.
A therapeutically effective dose of an agent refers to that
amount of the agent Which results in amelioration of symp
toms or a prolongation of survival in a subject. Toxicity and

US 8,629,163 B2
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therapeutic e?icacy of such molecules can be determined by
standard pharmaceutical procedures in cell cultures or experi
mental animals, e. g., by determining the LD5O (the dose lethal
to 50% of the population) and the ED5O (the dose therapeuti
cally effective in 50% of the population). The dose ratio of
toxic to therapeutic effects is the therapeutic index, Which can
be expressed as the ratio LDSO/EDSO. Agents that exhibit high
therapeutic indices are preferred.
Dosages preferably fall Within a range of circulating con

Was then added sloWly. The reaction Was alloWed to stir to

room temperature for 1 day and poured onto crushed ice. The
resulting solid Was collected by suction ?ltration and Washed
Well With methanol to remove iodine. The crude lavender

poWder (5.4 g 82% yield) Was crystalliZed from 2-methoxy
ethanol, giving 1,2,4,5-tetraiodobenZene (71% yield) as
White needles, mp 252-2550 C. 1H NMR (Me2SO-d6)
6 8.32 (s); 13C NMR (Me2SO-d6) 147.1, 108.5 ppm.
Example 2

centrations that includes the ED5O With little or no toxicity.

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

Dosages may vary Within this range depending upon the
dosage form employed and the route of administration uti
liZed. The exact formulation, route of administration, and
dosage should be chosen, according to methods knoWn in the
art, in vieW of the speci?cs of a subject’s condition.
The amount of agent or composition administered Will, of
course, be dependent on a variety of factors, including the sex,

tetrakis(4-pentyn-ol)

age, and Weight of the subject being treated, the severity of the
af?iction, the manner of administration, and the judgment of

20

HO

%

%

OH

25

HO

%

%

OH

the prescribing physician. Compounds of the present inven
tion Will generally be administered in an amount ranging
from about 1><10_5 to 100 mg/kg/day, With amounts in the

range of about 1><10_2 to 1 mg/kg/day being preferred.
The present compositions may, if desired, be presented in a
pack or dispenser device containing one or more unit dosage
forms containing the active ingredient. Such a pack or device
may, for example, comprise metal or plastic foil, such as a

blister pack. The pack or dispenser device may be accompa
nied by instructions for administration. Compositions com
prising a compound of the invention formulated in a compat
ible pharmaceutical carrier may also be prepared, placed in an
appropriate container, and labeled for treatment of an indi
cated condition.
These and other embodiments of the present invention Will

To a degassed solution of 1 ,2,4,5-tetraiodobenZene (5.81 g,
30

0.01 mol) in DMF-Et3N (100 mL, 1:1) Were added
Pd(PPh3)2Cl2 (350 mg. 0.5 mmol), Cul (200 mg, 1.2 mmol),
and 4-pentyn-1-ol (4.2 g, 0.05 mol) Was added drop-Wise. The
mixture Was stirred under N2 at room temperature for 24 h.
The solution Was poured into Water (400 mL). The mixture

35

readily occur to those of ordinary skill in the art in vieW of the

Was extracted With CH2Cl2 (3x200 mL). The combined
organic phases Were Washed With 5% HCl and brine, dried
over Na2SO4, and concentrated under vacuum. The residue

Was puri?ed by silica gel column chromatography using

disclosure herein, and are speci?cally contemplated.

CH2Cl2-MeOH (10:1, v/v) as eluent to afford tetramer (3.34
EXAMPLES
40

The invention is further understood by reference to the
folloWing examples, Which are intended to be purely exem
plary of the invention. The present invention is not limited in
scope by the exempli?ed embodiments, Which are intended as

illustrations of single aspects of the invention only. Any meth

g, 82%): 1H NMR (300 MHZ, CD3Cl+CO3OD 6 ppm), 7.30
(s, 2H), 3.72 (t, 1:63 HZ, 8H), 2.52 (t, J:7.2 HZ, 8H), 1.80 (p,
1:66 HZ, 8H) ppm.
Example 3

Preparation of 5 ,5',5 ", 5"'-(1 ,2,4,5 -benZentetrayl)
tetraki s( 1 -bromo-4 -p entyne)

45

ods that are functionally equivalent are Within the scope of the
invention. Various modi?cations of the invention in addition
to those described herein Will become apparent to those

skilled in the art from the foregoing description. Such modi
?cations fall Within the scope of the appended claims.
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Example 1

Preparation of 1,2,4,5-tetraiodobenZene
55

© IUI
l
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Br

%

%

Br

Br

%

%

Br

1

5 ,5',5 ", 5"'-(1 ,2,4,5 -benZentetrayl)tetrakis-4 -pentyn-ol

Periodic acid (2.56 g, 11.2 mmol) Was dissolved With stir

ring in concentrated H2SO4 (60 mL). Potassium iodide (5.58
g, 33.6 mmol) Was crushed and added to the clear solution.
After about 30 min of stirring, the dark mixture Was placed in
an ice bath. The aromatic substrate (C6H5, 1 mL, 11.2 mmol)

(2.05 g, 5.03 mmol) and carbon tetrabromide (7.41 g, 22.35
65

mmol) Were dissolved in dry methylene chloride (100 mL)
and cooled to 00 C. Triphenyl phosphine (6.16 g, 23 .47 mmol)
Was added portion-Wise and the mixture Was stirred at RT.

US 8,629,163 B2
19

20
5,5',5",5"'-(1,2,4,5-benZentetrayl)-tetrakis-pentan-1-ol

After the starting alcohol Was consumed methanol Was added
and the mixture Was stirred for an additional 5 minutes. The

(1.97 g, 4.67 mmol) and carbon tetrabromide (7.22 g,
21.74.80 mmol) Were dissolved in dry methylene chloride (50
mL) and cooled to 0° C. Triphenyl phosphine (5.70 g, 22.02

mixture concentrated and Was treated With hexanes (500 mL)
and then ?ltered through a short silica gel column, Washed

mmol) Was added portion-Wise and the mixture Was stirred at

With ethylacetate/hexanes (1/4). The combined organic sol- 5 RT. After the starting alcohol Was consumed methanol Was
vents Were evaporated to dryness under reduced pressure. The

added and the mixture Was stirred for an additional 5 minutes.

resulting residue Was puri?ed by column chromatography

The mixture concentrated and Was treated With hexanes (500

mL) and then ?ltered through a short silica gel column, and
Washed With ethylacetate/hexanes (1/4). The combined
organic solvents Were evaporated to dryness under reduced
pressure. The resulting residue Was puri?ed by column chro
matography (hexanes) to afford 2.83 g of the title compound.
Yield: 90%. 1H NMR (300 MHZ, CDCl3) 6 6.89 (s, 2H), 3.42

(hexanes) to afford 2.84 g of the title compound. Yield: 89%.

lHNMR (300 MHZ, CDCl3) 6 7.39 (s, 2H), 3.62 (t, 1:63 HZ,
8H), 2.67 (t, 1:66 HZ, 8H), 1.14 (p, 1:66 HZ, 8H) ppm.
Example 4

(t, J:7.2 HZ, 8H), 2.55 (m, 8H), 1.90 (m, 8H), 1.45-1.62 (m,
16H) ppm.
Example 6

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis-(pentan-l -ol)

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)
tetraki s [4-pentyn-1 -yl- (3 -methylpyridinium)]tetra
HO

OH

HO

OH

bromide
20
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%

%

Br

25

HO

OH

HO

OH

5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-4-pentyn-1-ol
(2.01 g, 4.95 mmol) Was dissolved in methanol (30 mL) and

30

10% Pd/C (5% W/W) Was added. The resulting mixture Was
6

hydrogenated on a Parr hydrogenation apparatus (45 psig) for
4 hrs. The catalyst Was removed by ?ltration through a Celite
pad. The ?lter cake Was rinsed With methanol, and the com
bined organic liquors Were concentrated under reduced pres
sure. The crude product Was puri?ed by column chromatog
raphy (CHCl3:MeOH, 10: 1) to afford 1.97 g of the title

compound. Yield: 95%. 1H NMR (300 MHZ, CDCl3) 6 6.81
(s, 3H), 3.62 (t, 1:63 HZ, 6H), 2.57 (t, 1:75 HZ, 6H), 1.53
1.70 (m, 12H), 1.38 (m, 6H) ppm; 13C NMR (75 MHZ,
CDCl3) 6 142.5, 126.1, 63.1, 36.1, 32.9, 31.5, 25.7 ppm.
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A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1

bromo-4-pentyne (300 mg, 0.46 mmol) and 3-picoline (607

Example 5

mg, 6.52 mmol) Was heated at 60-700 C. for 12 hrs. The
resulted mixture Was treated With diethyl ether and then dis
45 solved in Water (15 mL), the aqueous solution Was extracted

Preparation of 5',5",5"'-(1,2,4,5-benZentetrayl)-tet
rakis(1-bromopentane)

extensively With chloroform (30 mL><5). Water Was removed
by lyophiliZation to afford 385 mg of the title compound.
Yield: 82%. 1H NMR (300 MHZ, CD3OD) 6 9.01 9.11 (s,

HO

OH

HO

OH

_,

50

4H), 9.01 (d, 1:6 HZ, 4H), 8.38 (d, J:8.1 HZ, 4H), 8.01 (t,
11:6 HZ, 12:81 HZ, 4H), 7.41 (s, 2H), 4.88 (t, 1:84 HZ, 8H),
2.74 (t, 1:66 HZ, 8H), 2.57 (s, 12H), 2.40 (p, 1:66 HZ, 8H)
PPm~

Br

Br

Br

Br

Example 7
55

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis[4-pentyn-1 -yl-(4 -methylpyridinium)]tetra
rom1de

Br

%

%

Br

Br

%

%

Br
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Example 9

A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1

bromo-4-penyne (300 mg, 0.46 mmol) and 4-picoline (600
mg, 6.50 mmol) Was heated at 60-700 C. for 12 hrs. The
resulted mixture Was treated With diethyl ether and then dis
solved in Water (15 mL), the aqueous solution Was extracted

extensively With chloroform (30 mL><5). Water Was removed
by lyophiliZation to afford 408 mg of the title compound.
Yield: 87%. 1H NMR (300 MHZ, CD3OD) 6 ppm 8.95 (d,

Preparation of 5 ,5',5 ", 5"'-(1 ,2,4,5 -benZentetrayl)
tetraki s [4-pentyn-1 -yl- (3 ,5 -dimethylpyridinium)]
tetrabromide
20

1:60 HZ, 8H), 7.92 (d, 1:60 HZ, 8H), 7.37 (s, 2H), 4.82 (t,
1:63 HZ, 8H), 2.71 (t, 1:66 HZ, 8H), 2.58 (s, 12H), 2.35 (p,
1:66 HZ, 8H) ppm.

Br

Example 8
Br

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)
tetraki s [4-pentyn-1 -yl- (3 ,4 -dimethylpyridinium)]

//

tetrabromide
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A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1

-continued

bromo-4-pentyne (300 mg, 0.46 mmol) and 3,4-lutidine (650
mg, 5.0 mmol) Was heated at 60-700 C. for 12 hrs. The
resulted mixture Was treated With diethyl ether and then dis
solved in Water (15 mL), the aqueous solution Was extracted

extensively With chloroform (30 mL><5). Water Was removed
by lyophiliZation to afford 374 mg of the title compound.
Yield: 75%. 1H NMR (300 MHZ, CD3OD) 6 ppm 8.91 (s,

4H), 8.80 (d, 1:60 HZ, 4H), 7.85 (d, 1:66 HZ, 4H), 7.32 (s,
2H), 4.78 (t, 1:66 HZ, 8H), 2.71 (t, 1:63 HZ, 8H), 2.46 (s,
12H), 2.43 (s, 12H), 2.35 (t, 1:66 HZ, 8H) ppm.

65
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A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1bromo-4-pentyne (300 mg, 0.46 mmol) and 3,5-lutidine (650

8H), 8.17 (s, 4H), 7.39 (s, 4H), 4.79 (t, J:7.1 HZ, 8H), 2.72 (t,
1:66 HZ, 8H), 2.51 (s, 24H), 2.37 (t, 1:66 HZ, 8H) ppm.

mg, 5.0 mmol) Was heated at 60-700 C. for 12 hrs. The
resulted mixture Was treated With diethyl ether and then dis
solved in Water (15 mL), the aqueous solution Was extracted 5

extensively With chloroform (30 mL><5). Water Was removed
by lyophiliZation to afford 425 mg of the title compound.

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)
tetrakis(4-pentyn-1-yl-nicotinium)tetrabromide

Yield: 85%. 1H NMR (300 MHZ, CD3OD) 6 ppm 8.86 (s,

Br

Example 10

%

%

Br
—>

Br

%

%

Br

N/

\N

A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1
40

bromo-4-pentyne (300 mg, 0.46 mmol) and S(—)-nicotine
(320 mg, 2 mmol) in acetonitrile Was heated at 60-700 C. for
24 hrs. The resulted mixture Was treated With diethyl ether
and then dissolved in Water (1 5 mL), the aqueous solution Was

extracted extensively With chloroform (30 mL><5). Water Was
removed by lyophiliZation to afford 390 mg of the title com

45 pound. Yield: 60%. 1H NMR (300 MHZ, CD3OD) 6 99.15 (s,

4H), 9.05 (d, 1:6 HZ, 4H), 8.54 (d, J:7.8 HZ, 4H), 8.10 (t,
11:6 HZ, J2:7.8 HZ, 4H), 7.48 (s, 2H), 4.91 (t, J:7.5 HZ, 8H),
3.55 (t, J:8.1 HZ, 4H), 3.24 (m, 4H), 2.71 (t, J:8.1 HZ, 8H),
2.36-2.47 (m, 16H), 2.25 (s, 12H), 1.89-1.95 (m, 8H), 1.72
50 1.76 (m, 4H) ppm.
Example 1 1 1

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis[4-pentyn-1 -yl-(5, 6,7, 8-tetrahydroisoquino
linium)]tetrabromide

Br
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%
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%
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Br

B9

A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1- 15 (br, 16H). 13C NMR, 159.92, 145.40, 141.74,140.03, 136.20,
bromo-4-pentyne (300 mg, 0.46 mmol) and 5,6,7,8-tetrahy129.26, 126.28, 95.18, 80.49, 61.50, 30.94, 30.56, 27.51,
droisoquinoline (260 mg, 2.0 mmol) Was heated at 60-700 C.
22-30, 22-19, 1773 ppm
for 1 8 hrs. The resulted mixture Was treated With diethyl ether
and then dissolved in Water (15 mL), the aqueous solution Was
extracted extensively With chloroform (30 mL><5). Water Was 20
Exampk; 12
removed by lyophiliZation to afford 320 mg of the title com

pound.Yield: 80%. 1H NMR (300 MHZ) 6 (CD3Cl), 8.86 (s,
4H), 8.72 (d, 4H), 7.75 (s, 4H), 7.30 (s, 2H), 4.74 (t, J:8.1 HZ,
8H), 2.91 (br, 16H), 2.72 (t, 1:66 HZ, 8H), 2.35 (m, 8H), 1.80

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)
tetrakis[4-pentyn-1-yl-(3-phenyl-pyridinium)]tetra
bromide
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A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1
55 bromo-4-pentyne (300 mg, 0.46 mmol) and 3-phenylpyridine
(310 mg, 2.0 mmol) Was heated at 60-700 C. for 18 hrs. The
resulting mixture Was treated With diethyl ether and then
dissolved in Water (15 mL), the aqueous solution Was
extracted extensively With chloroform (30 mL><5). Water Was
60 removed by lyophiliZation to afford 440 mg of the title com

pound. Yield: 75%. 1H NMR (300 MHZ, CD3OD) 6 ppm 9.50

(s, 4H), 9.09 (d, 1:60 HZ, 4H), 8.73-8.76 (m, 4H), 7.12-7.16
(m, 4H), 7.76-7.81 (m, 8H), 7.52-7.57 (m, 12H), 7.23 (s, 2H),
4.95 (t, J:8.4 HZ, 8H), 2.71 (t, 1:66 HZ, 8H), 2.40 (m, 8H)
65 ppm. 13C NMR, 144.23, 142.61, 136.23, 134.47, 131.51,
130.78, 139.56, 128.70, 126.13, 94.82, 80.97, 62.58, 31.08,
17.68 ppm.
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Example 13

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis[4-pentyne-1-yl-(isoquinolinolinium)]tetra
bromide

Br

Br

%

A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1

bromo-4-pentyne (300 mg, 0.46 mmol) and isoquinoline (260

NMR, 144.23, 142.61, 136.23, 134.48, 131.51, 130.78,
129.56, 128.70, 126.13, 94.82, 80.97, 62.57, 31.08, 17.68

mg, 2.0 mmol) Was heated at 60-700 C. for 18 hrs. The

resulting mixture Was treated With diethyl ether and then
dissolved in Water (15 mL), the aqueous solution Was
extracted extensively With chloroform (30 mL><5). Water Was
removed by lyophiliZation to afford 442 mg of the title com

pound.Yield: 82%. 1H NMR (300 MHZ, CD3OD) 6 10.14 (s,
4H), 8.80 (d, 1:66 HZ, 4H), 8.47 (d, 1:75 HZ, *H), 8.147
8.17 (m, 8H), 8.00 (m, 4H), 6.59 (s, 2H), 5.02 (t, 1:66 HZ,
8H), 2.79 (t, 1:63 HZ, 8H), 2.44-2.50 (m, 8H) ppm. l3C

Br

Br

%

Example 14

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)
tetrakis [4 -pentyn- 1 -yl- (3 -benZyl-pyridinium)]tetra
bromide

%
%

Br

Br

US 8,629,163 B2
29

30

A mixture of 5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-1

-continued

bromo-4-pentyne (300 mg, 0.46 mmol) and 3-benZyl pyri
dine (340 mg, 2.0 mmol) Was heated at 60-700 C. for 18 hrs.
The resulting mixture Was treated With diethyl ether and then
dissolved in Water (15 mL), the aqueous solution Was 5

9
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extracted extensively With chloroform (30 mL><5). Water Was
removed by lyophiliZation to afford 521 mg of the title com

pound. Yield: 85%. 1H NMR (300 MHZ, CD3OD) 6 9.21 (s,

4H), 9.02 (d, 4H), 8.26 (d, 4H), 8.00 (dd, 4H), 7.42 (s, 2H),
7.18-7.28 (m, 20H), 4.86 (t, 8H), 4.22 (s, 8H), 2.67 (t, 8H),
2.34-2.44 (m, 8H) ppm.
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Example 15

Preparation of 5, 5',5 ", 5"'-(1 ,2,4, 5-benZentetrayl)

A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1

tetrakis {4-pentyn-1 -yl-[3-(3 -hydroxypropyl) -pyri

bromopentane] (330 mg, 0.49 mmol) and 3-picoline (220 mg,

dinium] }tetrabromide

2.3 mmol) Was heated at 60-700 C. for 18 hrs. The resulting
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A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1

pound. Yield: 63%. 1H NMR (300 MHZ, CD3OD) 6 9.14 (s,
4H), 9.04 (d, 1:60 HZ, 4H), 8.45 (d, J:8.1 HZ, 4H), 8.05 (dd,
11:60 HZ, 12:81 HZ, 4H), 7.39 (s, 2H), 4.90 (t, 1:69 HZ,
8H), 3.61 (t, 1:60 HZ, 8H), 2.96 (t, J:7.8 HZ, 8H), 2.75 (t,
1:66 HZ, 8H), 2.36-2.45 (m, 8H), 1.88-1.97 (m, 8H) ppm.
Example 16

sively With chloroform (30 mL><5). Water Was removed
45

through lyophiliZation to afford 400 mg of the title com

pound. Yield: 78%. 1H NMR (300 MHZ, CD3OD) 6 ppm 9.08
(s, 4H), 8.96 (d, 1:60 HZ, 4H), 8.47 (d, J:8.1 HZ, 4H), 8.02
(dd, J1:8.1 HZ, 12:60 HZ, 4H). 6.92 (s, 2H), 4.70 (t, J:7.8
50

HZ, 8H), 2.61 (s, 12H), 2.58 (t, J:7.8 HZ, 8H), 2.08-2.14 (m,
8H), 1.50-1.65 (m, 8H), 1.45-1.52 (m, 8H) ppm. 13C NMR,
146.10, 144.43, 141.97, 139.95, 137.35, 130.17, 127.60,
61.71, 32.07, 31.54, 31.09, 26.24, 17.79 ppm.
Example 17

55

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis[pentanyl-(4 -methyl-pyridinium)]tetrabro

tetrakis[pentanyl-(3 -methyl-pyridinium)]tetrabro
mide

OH

mixture Was treated With diethyl ether and then dissolved in
Water (15 mL), the aqueous solution Was extracted exten

bromo-4-pentyne] (300 mg, 0.46 mmol) and 3-hydroxypro
pylpyridine (340 mg, 2.0 mmol) Was heated at 60-700 C. for
18 hrs. The resulting mixture Was treated With diethyl ether
and then dissolved in Water (15 mL), the aqueous solution Was
extracted extensively With chloroform (30 mL><5). Water Was
removed by lyophiliZation to afford 350 mg of the title com

OH

N

mide

60

Br

Br

Br

Br

Br

Br

Br

Br
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extracted extensively With chloroform (30 mL><5). Water Was
removed through lyophiliZation to afford 421 mg of the title

Bre

Br (9 —

compound.Yield: 78%. 1H NMR (300 MHZ, CD3OD) 6 8.84
(s, 4H), 8.73 (d, 1:63 HZ, 4H), 7.86 (d, 1:63 HZ, 4H0, 6.89
(s, 2H), 4.57 (t, 1:75 HZ, 8H), 2.58 s, 12 H), 2.56 (t, 1:75 HZ,
8H), 2.48 (s, 12 H), 2.01-2.08 (m, 8H), 1.56-1.64 (m, 8H),
1.42-1.49 (m, 8H) ppm. 13C NMR, 158.40, 142.97, 141.35,

138.69, 137.28, 130.11, 128.27, 60.85, 32.04, 31.41, 31.08,
®

/ \N
—

(9

9

26.22, 15.94 ppm.

—

eN\ /

Br

Example 19

Br

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis[pentanyl-(3 ,5 -dimethyl-pyridinium)]tetra

Amixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1
bromopentane] (330 mg, 0.49 mmol) and 4-picoline (220 mg,

bromide

2.3 mmol) Was heated at 60-700 C. for 18 hrs. The resulting
mixture Was treated With diethyl ether and then dissolved in
Water (15 mL), the aqueous solution Was extracted exten

sively With chloroform (30 mL><5). Water Was removed
through lyophiliZation to afford 425 mg of the title com

pound. Yield: 83%. 1H NMR (300 MHZ, CD3OD) 6 8.97 (d,
1:66 HZ, 8H), 7.97 (d, 1:66 HZ, 8H), 6.91 (s, 2H), 4.67 (t,
1:75 HZ, 8H), 2.67 (s, 12 HZ), 2.57 (t, 1:75 HZ, 8H), 2.04
2.11 (m, 8H), 1.57-1.65 (m, 8H), 1.46-1.50 (m, 8H) ppm. 13C
NMR, 159.69, 143.48, 137.35, 130.17, 128.79, 61.01, 32.05,

Br

Br

Br

Br
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31.42, 31.09, 26.17 ppm.
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Example 18

\

/

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis[pentanyl-(3,4-dimethyl-pyridinium)]tetra

30

bromide

/ \1?
—

‘% —

6

Br

B? \

/

—>

Br

Br

A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1
40
G)

9

mg, 2.3 mmol) Was heated at 60-700 C. for 18 hrs. The

_

45

N

_

9 \

Br

resulting mixture Was treated With diethyl ether and then
dissolved in Water (15 mL), the aqueous solution Was
extracted extensively With chloroform (30 mL><5). Water Was
removed through lyophiliZation to afford 475 mg of the title

compound.Yield: 88%. 1H NMR (300 MHZ, CD3OD) 6 8.76
(s, 8H), 8.25 (s, 6.90 (s, 2H), 4.57 (t, J:7.8 HZ, 8H), 2.57 (t,
1:75 HZ, 2.53 (s, 12H), 2.03-2.08 (m, 8H), 2.58-1.64 (m,
8H), 1.45-1.50 (m, 8H) ppm. 13C NMR, 147.72, 142.75,

N

BIG

bromopentane] (330 mg, 0.49 mmol) and 3,5-lutidine (220

/

Amixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1
bromopentane] (330 mg, 0.49 mmol) and 3,4-lutidine (220

50

140.37, 138.52, 131.34, 62.77, 33.27, 32.73, 32.34, 27.53,
18.55 ppm.
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Example 20

mg, 2.3 mmol) Was heated at 60-700 C. for 18 hrs. The

resulting mixture Was treated With diethyl ether and then
dissolved in Water (15 mL), the aqueous solution Was

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

tetrakis[pentanyl-(nicotinium)]tetrabromide

Br

Br

Br

Br
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Amixtureof5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1bromopentane] (330mg, 04911111101) andS-(-)-njcotine (355

(m, 16 HZ), 1.74-1.78 (m, 4H), 1.61 (br, 8H), 1.48 (br, 8H)
ppm. 13C NMR, 145.80, 144.43, 143.72, 143.44, 137.28,

mg, 23 mmol) Was heated at 60-700 C_ for 18 hrs The 25 128.12, 67.45, 61.89, 56.79, 39.69, 35.14, 32.05, 31.55,
resulted mixture Was treated With diethyl ether and then dis31'06’ 26'25’ 2293 Ppm'
solved in Water (15 mL), the aqueous solution Was extracted
extensively With chloroform (30 mL><5). Water Was removed
through lyophiliZation to afford 362 mg of the title comExample 21

pound. Yield: 56%. 1H NMR (300 MHZ, CD3OD) 6 9.06 (s, 30

4H), 8.96 (d, 1:66 HZ, 4H), 8.57 (d, J:8.1 HZ, 4H), 8.07 (dd,

Preparation of 5,5',5",5"'-(1,2,4,5-benZentetrayl)

4H), 6.89 (s, 2H), 4.69 (t, 117.5 HZ, 8H), 3.54 (m, 4H),

tetrakis[pentanyl-(3-(3-hydroxypropanyl)pyri

3.24-3.34 (m, 4H), 2.38-2.59 (8H), 2.24 (s, 12H), 1.90-2.11

dinium)]tetrabromide

Br

Br

Br

Br
Br6

HO

(9

/ \N
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6
Br

OH
(9

\
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A mixture of5,5',5",5"'-(1,2,4,5-benZentetrayl)tetrakis-[1
55 bromopentane] (330 mg, 0.49 mmol) and 3-(3-hydroxypro
panyl)-pyridine (325 mg, 2.3 mmol) Was heated at 60-700 C.
for 18 hrs. The resulting mixture Was treated With diethyl
ether and then dissolved in Water (15 mL), the aqueous solu
tion Was extracted extensively With chloroform (30 mL><5).
Water Was removed through lyophiliZation to afford 371 mg
60 of the title compound. Yield: 62%. 1H NMR (300 MHZ,

CD3OD) 6 9.07 (s, 4H), 8.94 (d, 1:60 HZ, 4H), 8.50 (d, J:8.4
HZ, 4H), 8.05 (dd, 4H), 6.90 (s, 2H), 4.69 (t, J:7.5 HZ, 8H),
3.62 (t, 1:60 HZ, 8H), 2.99 (t, 7.8 HZ, 8H), 2.57 (t, J:7.5 HZ,
8H), 2.05-2.12 (m, 8H), 1.93-1.98 (m, 8H), 1.57-1.62 (m,
65 8H), 1.46-1.50 (m, 8H) ppm. 13C NMR, 145.53, 144.24,
143.98, 142.24, 137.30, 130.15, 127.80, 61.77, 60.48, 33.08,
32.05, 31.55, 31.06, 29.12, 26.20 ppm.

